La chaîne d'options affiche les données clés des options sur actions de Adaptimmune Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Adaptimmune Therapeutics..

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock, Chaîne d'Options

ADAPTIMMUNE THERAPEUTICS-ADR

Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adappter Token

AdaptHealth Corp

Adapti Inc

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Alpha Opportunities ETF

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Adaptive Core ETF

Adaptive Hedged Multi-Asset Income ETF

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst Ben Kallo downgraded the rating for Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) from Neutral to Underperform and maintained the price target of $60. Albemarle shares closed at $74.77 on Monday. <a href="https://www.benzinga.com/quote/alb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Lorraine Hutchinson downgraded Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) from Buy to Hold and raised the price target from $95 to $115. Tapestry shares closed at $110.42 on Monday. <a href="https://www.benzinga.com/quote/tpr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Clarke Jeffries downgraded Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) from Overweight to Neutral and raised the price target from $328 to $355. Cadence Design shares closed at $333.76 on Monday. <a href="https://www.benzinga.com/quote/cdns/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Arthur He downgraded the rating for Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) from Buy to Neutral. Adaptimmune Therapeutics shares closed at $0.1000 on Monday. <a href="https://www.benzinga.com/quote/adap/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Nicholas Yulico downgraded Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) from Sector Outperform to Sector Perform and lowered the price target from $21 to $19. Healthpeak Properties shares closed at $17.26 on Monday. <a href="https://www.benzinga.com/quote/doc/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ALB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ALB/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29091544/image-454-1024x576.png" alt="" class="wp-image-1005193" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29091544/image-454-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29091544/image-454-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29091544/image-454-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29091544/image-454.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="http://Sbenzinga.com/markets/equities/25/07/46679452/boeing-procter-gamble-and-3-stocks-to-watch-heading-into-tuesday">Boeing, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

ADAP

CDNS

This Albemarle Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

HC Wainwright &amp; Co. analyst Arthur He downgrades Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) from Buy to Neutral.

HC Wainwright & Co. Downgrades Adaptimmune Therapeutics to Neutral

<h3>Gainers</h3>
<ul>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) shares rose 17.0% to $0.12 during Monday's after-market session. The company's market cap stands at $91.9 million. </li>
<li>Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) shares moved upwards by 13.54% to $0.55. The company's market cap stands at $46.3 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock rose 10.9% to $0.7. The market value of their outstanding shares is at $8.1 million. </li>
<li>PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) stock moved upwards by 8.25% to $48.0. The company's market cap stands at $3.5 billion. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock increased by 6.88% to $8.38. The company's market cap stands at $4.3 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock increased by 6.62% to $17.37. The company's market cap stands at $736.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares decreased by 18.9% to $2.36 during Monday's after-market session. The company's market cap stands at $18.1 million. As per the press release, Q2 earnings came out 3 days ago. </li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) shares decreased by 13.27% to $38.5. The market value of their outstanding shares is at $12.4 billion. As per the press release, Q2 earnings came out today. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares declined by 8.7% to $36.0. The market value of their outstanding shares is at $4.2 billion. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) stock declined by 6.61% to $2.12. The market value of their outstanding shares is at $380.1 million. </li>
<li>Eledon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) shares fell 6.2% to $3.03. The company's market cap stands at $216.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares decreased by 5.8% to $4.0. The company's market cap stands at $58.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACON

ADIL

ATNF

ELDN

EXEL

MAZE

MLSS

MTSR

NMRA

PTCT

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) stock increased by 186.2% to $39.41 during Monday's regular session. The company's market cap stands at $521.4 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares rose 28.9% to $15.42. The market value of their outstanding shares is at $67.5 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares moved upwards by 25.55% to $0.4. The market value of their outstanding shares is at $19.1 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock moved upwards by 20.99% to $0.62. The company's market cap stands at $8.1 million. </li>
<li>Hyperion DeFi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPD#NASDAQ">HYPD</a>) stock rose 17.59% to $9.05. The market value of their outstanding shares is at $39.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) stock moved upwards by 17.3% to $2.13. The company's market cap stands at $13.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 66.2% to $0.12 during Monday's regular session. The company's market cap stands at $91.9 million. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) shares declined by 27.61% to $0.71. The company's market cap stands at $12.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 24.76% to $0.55. The company's market cap stands at $25.2 million. </li>
<li>TAO Synergies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOX#NASDAQ">TAOX</a>) stock decreased by 17.37% to $6.95. The company's market cap stands at $19.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.52% to $9.6. The company's market cap stands at $8.2 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares decreased by 14.66% to $5.59. The company's market cap stands at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CANF

CELC

CLDI

HYPD

SCLX

TAOX

XFOR

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday.
The Dow traded up 0.07% to 44,932.70 while the NASDAQ rose 0.28% to 21,167.71. The S&amp;P 500 also rose, gaining, 0.09% to 6,394.33.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Energy shares jumped by 0.9% on Monday.
In trading on Monday, materials stocks dipped by 1.1%.
Top Headline
The United States has temporarily halted restrictions on technology exports to China, according to a Monday report from the Financial Times. This pause is intended to prevent disruptions to ongoing trade discussions with Beijing and to bolster President Donald Trump's push for a meeting with Chinese President Xi Jinping later this year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>CEA Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAPE#NASDAQ">VAPE</a>) shares shot up 600% to $62.10 after the company announced a $500 million private placement.</li>
<li>Shares of Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) got a boost, surging 167% to $36.80 after the company released topline results from its PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares were also up, gaining 41% to $11.82 after the company announced mid-year data from its Phase 2 DURIPANC trial.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>) shares dropped 84% to $0.21. Quhuo announced a strategic partnership with NIU World to jointly establish a new chain brand incubation platform focused on fresh beef, built upon a localized supply chain in China.</li>
<li>Shares of Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) were down 63% to $0.1271 after the company announced it has agreed to sell Tecelra and other assets related to its cell therapy products for $55 million.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) was down, falling 44% to $1.1200 after the company announced a $7.5 million public offering.</li>
</ul>
Commodities In commodity news, oil traded up 2.2% to $66.57 while gold traded down 0.9% at $3,306.90.
Silver traded down 0.3% to $38.235 on Monday, while copper fell 1% to $5.7285.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.19%, while Spain's IBEX 35 Index slipped 0.09%. London's FTSE 100 fell 0.57%, Germany's DAX 40 declined 0.89% and France's CAC 40 fell 0.37% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 falling 1.10%, Hong Kong's Hang Seng gaining 0.68%, China's Shanghai Composite rising 0.12% and India's BSE Sensex falling 0.70%.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

SIDU

VAPE

Crude Oil Gains 2%; CEA Industries Shares Spike Higher

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 50 points on Monday.
Following the market opening Tuesday, the Dow traded down 0.14% to 44,837.21 while the NASDAQ rose 0.35% to 21,181.60. The S&amp;P 500 also rose, gaining, 0.07% to 6,393.09.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Energy shares jumped by 0.9% on Monday.
In trading on Monday, materials stocks dipped by 1.3%.
Top Headline
Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) reported better-than-expected earnings for the second quarter.
The company posted quarterly earnings of 66 cents per share which beat the analyst consensus estimate of 64 cents per share. The company reported quarterly sales of $11.36 billion which missed the analyst consensus estimate of $14.19 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>CEA Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAPE#NASDAQ">VAPE</a>) shares shot up 513% to $54.37 after the company announced a $500 million private placement.</li>
<li>Shares of Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) got a boost, surging 220% to $44.10 after the company released topline results from its PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares were also up, gaining 77% to $14.85 after the company announced mid-year data from its Phase 2 DURIPANC trial.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>) shares dropped 77% to $0.31. Quhuo announced a strategic partnership with NIU World to jointly establish a new chain brand incubation platform focused on fresh beef, built upon a localized supply chain in China.</li>
<li>Shares of Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) were down 64% to $0.1256 after the company announced it has agreed to sell Tecelra and other assets related to its cell therapy products for $55 million.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) was down, falling 44% to $1.1350 after the company announced a $7.5 million public offering.</li>
</ul>
Commodities In commodity news, oil traded up 2.3% to $66.66 while gold traded down 0.6% at $3,316.50.
Silver traded down 0.4% to $38.205 on Monday, while copper fell 0.8% to $5.7395.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.1%, while Spain's IBEX 35 Index rose 0.1%. London's FTSE 100 fell 0.5%, Germany's DAX 40 declined 0.7% and France's CAC 40 fell 0.2% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 falling 1.10%, Hong Kong's Hang Seng gaining 0.68%, China's Shanghai Composite rising 0.12% and India's BSE Sensex falling 0.70%.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shutterstock

US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings

WIIM

Adaptimmune Therapeutics shares are trading lower after the company announced it has agreed to sell Tecelra and other assets related to its cell therapy products for $55 million.

<h3>Gainers</h3>
<ul>
<li>Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) stock rose 241.8% to $47.06 during Monday's pre-market session. The market value of their outstanding shares is at $521.4 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock rose 41.31% to $12.69. The company's market cap stands at $78.1 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) stock increased by 17.73% to $2.39. The company's market cap stands at $187.0 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 17.69% to $3.48. The company's market cap stands at $70.8 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 17.31% to $0.37. The company's market cap stands at $19.1 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 17.22% to $0.08. The market value of their outstanding shares is at $27.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 36.6% to $0.22 during Monday's pre-market session. The market value of their outstanding shares is at $91.9 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares fell 16.04% to $5.5. The company's market cap stands at $96.9 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 13.34% to $2.6. The market value of their outstanding shares is at $18.1 million. As per the press release, Q2 earnings came out 3 days ago. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock fell 11.4% to $0.65. The market value of their outstanding shares is at $25.2 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares fell 9.19% to $1.64. The company's market cap stands at $36.4 million. </li>
<li>Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) shares fell 7.4% to $96.0. The company's market cap stands at $12.2 billion. As per the press release, Q2 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAMP

CELU

CRVO

HCTI

IPHA

RVTY

12 Health Care Stocks Moving In Monday's Pre-Market Session

On July 27, 2025, Adaptimmune Limited ("Seller"), a wholly-owned subsidiary of Adaptimmune Therapeutics plc (together with Seller, "Adaptimmune" or the "Company"), entered into an Asset Purchase Agreement (the "Agreement") with USWM CT, LLC ("Purchaser"), a subsidiary of US WorldMeds Partners, LLC ("Parent", and together with Purchaser, "US WorldMeds") and Parent (solely for the purposes of Section 10.14 of the Agreement).
&nbsp;
Pursuant to the terms set forth in the Agreement, Adaptimmune agreed to sell to Purchaser the assets and rights related to Adaptimmune's TECELRA, lete-cel, afami-cel and uza-cel cell therapies (the "Products"), and Purchaser agreed to assume certain liabilities related to the Products (the "Transaction"). Adaptimmune also agreed to transfer to Seller specified intellectual property, product rights, regulatory authorizations, contracts, equipment, inventory, and other related assets. In connection with the Transaction, US WorldMeds intends to offer employment to approximately half of the Company's workforce.
&nbsp;
Upon consummation of the Transaction, Purchaser will pay $55,000,000 in cash, a portion of which Purchaser will pay directly to Hercules Capital, Inc. ("Hercules") to repay all of Adaptimmune's indebtedness under that certain Loan and Security Agreement, dated May 14, 2024, by and among Adaptimmune, Hercules and the other parties thereto. In addition, Purchaser has agreed to make future payments to Adaptimmune of up to $30,000,000 in cash upon the achievement of certain regulatory and commercial milestones related to the Products within certain specified time periods and subject to certain specified reductions, including:

Biotech

General

Adaptimmune Limited, A Subsidiary Of Adaptimmune Therapeutics Plc  Announces It Entered Into An Asset Purchase Agreement With USWM CT, A Subsidiary Of US WorldMeds Partners, Llc, To Sell Assets And Rights Related To Its Cell Therapy Products Offer Employment To Approximately Half Of Adaptimmune's Workforce. In Exchange, UU WorldMeds Will Pay $55M In Cash

<ul>
<li>Under the terms of the asset purchase agreement, US WorldMeds will purchase the TECELRA, uza-cel, afami-cel and lete-cel cell therapy assets of Adaptimmune (the "Assigned Assets") and all intellectual property rights exclusively relating to such Assigned Assets. In return, Adaptimmune will receive $55 million in cash upon consummation of the sale. In addition, US WorldMeds has agreed to make future payments of up to $30 million to Adaptimmune upon the achievement of certain milestones. Adaptimmune and US WorldMeds will also enter into a license agreement pursuant to which, among other things, US WorldMeds will be exclusively licensed residual intellectual property rights necessary for the manufacture and commercialization of the Assigned Assets and non-exclusively licensed intellectual property rights in Adaptimmune's vector manufacturing process. Adaptimmune will also provide certain transition services to US WorldMeds pursuant to a transition services agreement on terms specified therein.</li>
<li>US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos</li>
<li>Purchase price is $55m in cash to be paid upon consummation of the sale with up to $30m in potential future payments upon achievement of certain milestones</li>
<li>Adaptimmune will retain rights to its preclinical assets including PRAME, CD70, and its allogeneic program</li>
<li>Adaptimmune will restructure to support the transition of these therapies to US WorldMeds and to maximize value from its remaining assets</li>
<li>Adaptimmune's Board of Directors determined this transaction is in the best interest of all stakeholders following a comprehensive review of all strategic alternatives &nbsp;</li>
</ul>

Health Care

Adaptimmune Therapeutics Agreed To Sell Tecelra, Lete-cel, Afami-cel, And Uza-cel Cell Therapies To US WorldMeds For $55M And Milestone Payment Of Up To $30M

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Janardan Menon downgraded the rating for ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) from Buy to Hold. ASML shares closed at $815.24 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Alec Brondolo downgraded The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from Overweight to Equal-Weight and lowered the price target from $74 to $68. Trade Desk shares closed at $69.80 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Jordan Bender downgraded MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) from Market Outperform to Market Perform. MGM Resorts shares closed at $33.88 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Graig Suvannavejh downgraded Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) from Outperform to Neutral and cut the price target from $1.5 to $0.5. Adaptimmune Therapeutics shares closed at $0.2530 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Eliana Merle downgraded CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) from Buy to Neutral and lowered the price target from $12 to $5.5. CureVac shares closed at $5.44 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TTD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ttd/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26084214/image-408-1024x576.png" alt="" class="wp-image-963223" style="width:626px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26084214/image-408-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26084214/image-408-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26084214/image-408-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26084214/image-408.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ASML

CVAC

IDYA

SNDK

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Mizuho analyst Graig Suvannavejh downgrades Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) from Outperform to Neutral and lowers the price target from $1.5 to $0.5.

Price Target

Mizuho Downgrades Adaptimmune Therapeutics to Neutral, Lowers Price Target to $0.5

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 8.5% to $1.15 during Thursday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock rose 7.1% to $8.59. The market value of their outstanding shares is at $104.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 7.07% to $0.26. The company's market cap stands at $69.7 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) stock moved upwards by 6.58% to $5.5. The market value of their outstanding shares is at $30.2 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 5.91% to $0.33. The company's market cap stands at $1.4 million. </li>
<li>Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) stock increased by 5.52% to $4.2. The company's market cap stands at $292.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 16.3% to $0.03 during Thursday's after-market session. The company's market cap stands at $10.2 million. </li>
<li>Rein Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>) shares declined by 12.7% to $1.72. The market value of their outstanding shares is at $38.1 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares decreased by 10.79% to $18.12. The company's market cap stands at $471.3 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares declined by 8.63% to $0.28. The market value of their outstanding shares is at $7.5 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock decreased by 8.19% to $4.15. The market value of their outstanding shares is at $388.2 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 6.52% to $0.14. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CMPS

HCAT

LIMN

NCNA

NUWE

PLRZ

RNTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Adaptimmune Therapeutics, presenting an average target of $1.52, a high estimate of $3.00, and a low estimate of $0.46. A negative shift in sentiment is evident as analysts have decreased the average price target by 35.59%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747256431_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Adaptimmune Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$0.46</td>
<td>$1.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.00</td>
<td>$1.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1.75</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1.40</td>
<td>$3.15</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adaptimmune Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Adaptimmune Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Adaptimmune Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Adaptimmune Therapeutics's Background</h2>
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
<h3>Breaking Down Adaptimmune Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Adaptimmune Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1294.81% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Adaptimmune Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2303.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -161.62%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -26.35%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Adaptimmune Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 6.26. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Adaptimmune Therapeutics

Barclays analyst Peter Lawson maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Underweight and lowers the price target from $1 to $0.46.

Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $0.46

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Equal-Weight and lowers the price target from $1.5 to $1.

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1

ADAP stock has given up its prior gain. Adaptimmune Therapeutics shares were trading higher after the company reported better-than-expected Q1 financial results.

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.12) by 75 percent. This is unchanged from the same period last year. The company reported quarterly sales of $7.29 million which beat the analyst consensus estimate of $6.17 million by 17.99 percent. This is a 28.30 percent increase over sales of $5.68 million the same period last year.

Earnings Beats

Adaptimmune Therapeutics Q1 EPS $(0.03) Beats $(0.12) Estimate, Sales $7.29M Beat $6.17M Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Press Releases

Adaptimmune Reports Q3 2024 Financial and Business Updates

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

AFFX

Comments

Adaptimmune Therapeutics

Adaptimmune Therapeutics (ADAP) Options

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL